Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma

July 26, 2022 updated by: Nagwa Abd El-Sadek Ahmed, Sohag University
Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis. CXCL5 have been implicated in progression of many cancers, but their significance in urinary bladder UC remains unclear.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Bladder carcinoma has become a common cancer globally, Incidence rates are highest in Europe, the United States and Egypt. In Egypt, bladder carcinoma was considered the third most common tumor; Egyptian males have the highest mortality rates. UC of the urinary bladder represents about 90% of all bladder cancers.

CXCL5 is a chemokine, belonging to ‗ELR+' subgroup. It plays an important role in angiogenesis and tumor migration. Numerous reports have indicated that CXCL5 plays important roles in cancer progression, including cholangiocarcinoma, prostate cancer, and gastric cancer. Studying the IHC expression of CXCL5 in UC to assess its role in tumor cell proliferation, migration and spread is needed.

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Sohag, Egypt
        • Recruiting
        • Faculty of Medicine, Sohag University
        • Contact:
          • Ahmed Roshdi, Assist. prof

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Fifty specimens of urothelial carcinoma obtained from patients in Urology Department of Sohag Faculty of Medicine,

Description

Inclusion Criteria:Patients with primary invasive and non-invasive urinary bladder urothelial carcinomas.

-

Exclusion Criteria:

  • - Patients received pre-operative chemotherapy or radiotherapy.
  • Patients with insufficient clinical data.
  • Specimens with extensive necrosis
  • Tiny specimens which are insufficient for accurate diagnosis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
assess the expression of CXCL5 in urothelial carcinoma
Time Frame: 1 month
Immunohistochemical study
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Principal Investigator: Nagwa Ahmed, Lecturer, Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2022

Primary Completion (Actual)

May 1, 2022

Study Completion (Anticipated)

July 30, 2022

Study Registration Dates

First Submitted

November 9, 2021

First Submitted That Met QC Criteria

November 24, 2021

First Posted (Actual)

December 1, 2021

Study Record Updates

Last Update Posted (Actual)

July 29, 2022

Last Update Submitted That Met QC Criteria

July 26, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-21-10-43

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Bladder Urothelial Carcinoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe